Aker BioMarine

Share Issue/Capital Change • Feb 28, 2022

Aker BioMarine ASA – Result of the offer under the Employee Share Purchase Program and share capital increase

Aker BioMarine ASA – Result of the offer under the Employee Share Purchase Program and share capital increase

28 February 2022: Reference is made to Aker BioMarine ASA's (the "Company") stock exchange announcement on 17 February 2022, regarding the offer of new shares to employees in the Company and its Norwegian subsidiaries (the "Employee Share Purchase Program"). The deadline for acceptance of the offer in the Employee Share Purchase Program expired today, on 28 February 2022, at 16:30 CET.

The offer price for the shares in the Employee Share Purchase Program has been set to approximately NOK 37.078 per share (the "Offer Price"). The Offer Price is based on the volume weighted average share price for the Company's shares on the Oslo Stock Exchange during the last five trading days prior to, and including, the last day of the application period, with a discount of 20%. Any shares acquired in the Employee Share Purchase Program will be subject to a lock-up period of two years, and the reduced offer price shall reflect the value-reducing effect of the lock-up period.

Based on the applications received in the Employee Share Purchase Program, the board of directors of the Company has allocated a total of 51 647 new shares to the participants in the Employee Share Purchase Program (the "Program Shares").

Furthermore, the board of directors has, on the basis of the authorisation granted to it by the annual general meeting held on 12 March 2021, resolved to increase the share capital of the Company with NOK 309 882, by issuance of 51 647 new shares, each with a nominal value of NOK 6.00, at a subscription price equal to the Offer Price. The Program Shares comprise approximately 0.06% of the existing and outstanding shares in the Company prior to their issuance.

Following the registration of the share capital increase with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret), the new share capital of the Company will be NOK 525 826 398, divided into 87 637 733 shares, each with a nominal value of NOK 6.00.

For further information please contact:

Carl Christian Bachke, Investor Relations

Mobile: +47 909 808 48

Email: carl.bachke@akerbiomarine.com

About Aker BioMarine ASA

Aker BioMarine is a leading biotech innovator and Antarctic krill-harvesting company developing krill-derived products for pharma, consumer health and wellness as well as animal nutrition. The company has a strong position in its industry and is the world's leading supplier of krill, the natural, powerful and health promoting source of nutrients from the pristine waters of Antarctica. Aker BioMarine is listed on Oslo Stock Exchange (AKBM). More information is available at www.akerbiomarine.com.